WHO Pharmaceuticals Newsletter 1999, No. 01&02
(1999; 16 pages)
Table of Contents
Open this folder and view contentsRegulatory actions
Open this folder and view contentsDrug surveillance
Open this folder and view contentsNew developments
Open this folder and view contentsGeneral information
Close this folderMedication errors
View the documentDecimal dosages: confusion: USA
View the documentEltroxin (levothyroxine sodium): confusion in formulations: Ireland
View the documentPegaspargase (Oncaspar): misleading graphics: USA
View the documentRemeron (mirtazepine): strength confusion: USA
View the documentTiagabine and tizanidine: name confusion and similar dosing and tablet strength: USA
View the documentWarfarin (Coumadin): confusing instructions: USA
Open this folder and view contentsVeterinary medicine
 

Tiagabine and tizanidine: name confusion and similar dosing and tablet strength: USA

United States of America. Similar dosing and tablet strength for two drugs with look-alike generic names, tiagabine (Gabatril: Abbott) and tizanidine (Zanaflex: Athena Neurosciences) increases the potential for confusing these products.

Tiagabine, used to treat seizures, is available in 4 mg tablets with a dosage range from 4 mg daily to 8 mg four times daily. Tizanidine, used to treat muscle spasticity, is also available in 4 mg tablets with a dosage range of 4 mg to 8 mg every 6 to 8 hours.

Reference: ISMP Medication Safety Alert! Vol. 3, Issue 24, 1 December 1998.

to previous section to next section
 

Last updated: May 3, 2013